Tadatoshi Takayama

Tadatoshi Takayama

Auto-generated profile, based on publicly available information

Tadatoshi Takayama

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2003 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TETeruo Eguchi
Teruo Eguchi
MFMasashi Fujii
Masashi Fujii
TTTadatoshi Takayama
Tadatoshi Takayama

24 May 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KTKiyoko Takane
Kiyoko Takane
YMYutaka Midorikawa
Yutaka Midorikawa
KYKoichi Yagi
Koichi Yagi
ASAyako Sakai
Ayako Sakai
HAHiroyuki Aburatani
Hiroyuki Aburatani
AKAtsushi Kaneda
Atsushi Kaneda
Aberrant DNA methylation is a common epigenetic alteration involved in colorectal cancer (CRC). In our previous study, we performed methylated DNA immunoprecipitation‐on‐chip analysis combined with gene re‐expression analysis by 5‐aza‐2′‐deoxycytidine treatment, to identify methylation genes in CRC genome widely. Among these genes, 12 genes showed aberrant hypermethylation frequently in >75% of 149 CRC samples but did not in normal samples. In this study, we aim to find out any of these methylation genes to be utilized for CRC detection using plasma DNA samples. Primers for methylation‐specific PCR and pyrosequencing were designed for seven of the 12 genes. Among them, PPP1R3C and EFHD1 were rarely hypermethylated in peripheral blood cells, but frequently hypermethylated in 24 CRC tissue samples and their corresponding plasma samples. In plasma samples, PPP1R3C was methylated in 81% (97/120) of CRC patients, but only in 19% (18/96) of noncancer patients (P = 6 × 10−20, Fisher's exact test). In combined analysis with EFHD1, both genes were methylated in 53% (64/120) of CRC patients, but only in 4% (4/96) of noncancer patients (P = 2 × 10−16), giving high specificity of 96%. At least one of the two genes was methylated in 90% (108/120) of CRC patients, and 36% (35/96) of control patients, giving high sensitivity of 90%. Compared with low sensitivity of carcinoembryonic antigen (17% at stage I, 40% at stage II) and CA19‐9 (0% at stage I, 13% at stage II) for early‐stage CRCs, sensitivity of aberrant methylation was significantly higher: PPP1R3C methylation at 92% (11/12) for stage I and 77% (23/30) for stage II, and methylation of at least one gene at 100% (12/12) for stage I and 87% (26/30) for stage II. PPP1R3C methylation or its combined use of EFHD1 methylation was highly positive in CRC plasma samples, and they might be useful in detection of CRC, especially for early‐stage CRCs.

19 February 2014 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
OAOsamu Aramaki
Osamu Aramaki
TTTadatoshi Takayama
Tadatoshi Takayama
THTokio Higaki
Tokio Higaki
HNHisashi Nakayama
Hisashi Nakayama
TOTakao Ohkubo
Takao Ohkubo
YMYutaka Matsuyama
Yutaka Matsuyama

21 November 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
MKMitsugu Kochi
Mitsugu Kochi
MFMasashi Fujii
Masashi Fujii
SMShinobu Masuda
Shinobu Masuda
NKNoriaki Kanamori
Noriaki Kanamori
YMYoshiaki Mihara
Yoshiaki Mihara
TTTadatoshi Takayama
Tadatoshi Takayama
The aim of this study was to investigate how differences in expression of HER2 between primary gastric cancers (PGCs) and their corresponding metastatic lymph nodes (LMNs) might affect its potential as a prognostic indicator in treatments including anti-HER2 agents.

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
OAOsamu Aramaki
Osamu Aramaki
TTTadatoshi Takayama
Tadatoshi Takayama
MMMasamichi Moriguchi
Masamichi Moriguchi
HSHidemori Sakamoto
Hidemori Sakamoto
HYHiraku Yodono
Hiraku Yodono
MFMasashi Fujii
Masashi Fujii

27 January 2003 in Transplantation
Verified
Journal Article
Closed access
OAOsamu Aramaki
Osamu Aramaki
TTTadatoshi Takayama
Tadatoshi Takayama
TYTakeshi Yokoyama
Takeshi Yokoyama
STSeigo Takano
Seigo Takano
YAYoshinobu Akiyama
Yoshinobu Akiyama
MNMasanori Niimi
Masanori Niimi
The authors investigated whether antithrombin III (AT-III) could induce unresponsiveness to alloantigens. CBA mice were given intravenous injection of 50 or 500 U/kg AT-III or control plasma the same day as transplantation of a heart from a C57BL/6 mouse. An adoptive transfer study and mixed leukocyte culture analysis were also performed. Naive CBA mice rejected C57BL/6 cardiac grafts acutely (median survival time [MST], 9 days). The 50-U/kg dose of AT-III induced a moderate increase in graft survival (MST, 25 days), whereas control mice rejected their graft acutely (MST, 7 days). With the 500-U/kg dose of AT-III, all grafts survived indefinitely (>100 days) and regulatory cells were generated. In vitro, AT-III suppressed proliferation of mixed leukocyte responses and generation of interleukin-2. AT-III can be not only an antithrombotic agent but also a strong immunomodulating agent when used at high dose.